Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

FAQs

Show all

Agios is headquartered at 88 Sidney Street, 2nd floor, Cambridge, MA 02139, U.S.

The main phone number is (617) 649-8600.
Agios is traded on the NASDAQ global stock exchange under the ticker symbol AGIO, and its CUSIP number for the common stock is 00847X 104.
Agios’ initial public offering (IPO) occurred on July 24, 2013.
Agios will end the fiscal year on December 31st.
Communication regarding transfer requirements, lost certificates and changes of address should be directed to:

American Stock Transfer & Trust Company
(800) 937-5449 (Toll-free)
(718) 921-8124 (International)
http://www.amstock.com/new/InvestorServices/ShareholderServices.aspx
 
If delivering by mail:

American Stock Transfer & Trust Company Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, NY 10272-2042
  If delivering by hand or courier:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, NY 11219
Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116
+1 617 266 2000
Agios press release archives can be viewed at https://agiospharmaceuticalsinc.nasdaq.acsitefactory.com/news-releases/?field_nir_news_date_value%5Bmin%5D=2017#views-exposed-form-widget-news-widget-news-ul
Agios’ SEC filings can be viewed at https://agiospharmaceuticalsinc.nasdaq.acsitefactory.com/financial-information/sec-filings or www.sec.gov
You can submit queries to Agios’ investor relations department by contacting investors@agios.com.